China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced a licensing agreement with an unnamed Brazilian partner. The agreement grants the Brazilian company the rights to commercialize Boan Bio’s BA6101 and BA1102 in the local market as their Marketing Authorization Holder (MAH). Boan Bio will handle the commercial manufacturing of the drugs and will receive undisclosed upfront and milestone payments, in addition to sales commissions.
Biosimilar Versions of Amgen’s Prolia and Xgeva BA6101 and BA1102 are biosimilar versions of the US major Amgen’s Prolia (denosumab) and Xgeva (denosumab), respectively. Prolia is a widely used treatment for osteoporosis globally, while Xgeva is indicated for the treatment of solid tumor bone metastasis, multiple myeloma, giant cell tumor of bone, and hypercalcemia around the world.
Implications of the Licensing Agreement This licensing agreement positions Boan Bio to expand its global footprint and tap into the Brazilian market with its biosimilar products. The partnership is expected to enhance patient access to these essential treatments in Brazil, potentially offering more affordable options to the local population.-Fineline Info & Tech
Leave a Reply